Argos Therapeutics- data on murine model by Cellthera to determine functional activity of therapy modeled after co's AGS-003 individualized immunotherapy * Argos Therapeutics- data showed ...

"Our agreement with Argos to develop AGS-003 in China, Hong Kong, Taiwan and Macau is another example of our ongoing commitment to develop and market new therapies that can address serious unmet ...

Argos's Arcelis(TM) immunotherapy, AGS-003, has also been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with mRCC.

SAN FRANCISCO—An immunotherapy (AGS-003) in combination with sunitinib may help prolong the lives of men with unfavorable risk, metastatic renal cell carcinoma (mRCC), according to new data from ...